Harmony Biosciences Holdings Inc (HRMY) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Harmony Biosciences Holdings inc   (NASDAQ: HRMY)


Harmony Biosciences Holdings Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Harmony Biosciences Holdings Inc's ROI in the second quarter of 2026?
Harmony Biosciences Holdings inc achieved a return on average invested assets (ROI) of 15.85 % in its second quarter of 2026, which is below Harmony Biosciences Holdings Inc's average return on investment, which stands at 18.61%.

ROI has improved compared to 13.07% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 68 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 598.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 25.98 % 35.24 % 46.75 % 42.23 % 33.59 %
Y / Y Net Income Change TTM 0.2 % -4.65 % 48.09 % 221.88 % 1460.73 %
Investment (TTM) in Millions 1,162 1,054 1,211 1,146 1,046
Return On Investment (TTM) 15.85 % 13.07 % 14.44 % 18.52 % 19.93 %
HRMY's Overall Ranking # 598 # 598 # 211 # 91 # 257
Seq. Investment Change TTM 2.6 % 1.4 % 9.64 % 10.45 % 10.14 %
Seq. Net Income Change TTM 24.49 % -8.24 % -14.54 % 2.64 % 18.46 %
Net Income (TTM) in Millions 181 146 159 186 181

HRMY Company Profile >> Back to HRMY Roi Comparisons >> See Annual HRMY Return On Investment



Return On Investment HRMY's Ranking
Within: No.
Industry # 32
Sector # 69
Overall # 598

Return On Investment Statistics
High Average Low
36.66 %
18.61 %
2.65 %
(Dec 31 2022)   (Sep 30 2020)







Financial Statements
Harmony Biosciences Holdings Inc's II. Quarter Investments $ 1,162 Millions HRMY's Balance sheet
Harmony Biosciences Holdings Inc's II. Quarter Income $ 75 Millions Quarterly HRMY's Income Statement
HRMY's Income by Division See HRMY's Income by Division


HRMY Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,019 824 648 595 380
Y / Y Investment Growth 23.71 % 27.24 % 8.85 % 56.71 % 29.79 %
Net Income in Millions 159 145 129 181 35
Y / Y Net Income Growth 9.07 % 12.91 % -28.99 % 424.52 % -
Annual Return On Investment 15.57 % 17.65 % 19.89 % 30.5 % 9.11 %


Annual Roi Comment
In the fiscal year 2025 ROI deteriorated to 15.57 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HRMY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HRMY's Competitors
Subscribers only: Roi for Harmony Biosciences Holdings Inc's Suppliers
Subscribers only: Return On Investment for HRMY's Customers

Other Ratios
HRMY's Roa HRMY's Inventory Turnover Ratio HRMY's Growth Rates HRMY's Dividend Statistics
HRMY's Profitability Ratios HRMY's Asset Turnover Ratio HRMY's Dividend Growth
HRMY's Roe HRMY's Valuation Ratios HRMY's Financial Strength Ratios HRMY's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %

Date modified: 2026-09-26T07:38:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.